GLP1R and pancreatic neoplasm: This was demonstrated in a recent comparison of patients treated with GLP1-RAs to patients who received insulin, with regard to esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancer, meningioma and multiple myeloma.16